ES2746150T3 - Sistema de genética inversa para el virus Pichindé y métodos de uso - Google Patents

Sistema de genética inversa para el virus Pichindé y métodos de uso Download PDF

Info

Publication number
ES2746150T3
ES2746150T3 ES15772173T ES15772173T ES2746150T3 ES 2746150 T3 ES2746150 T3 ES 2746150T3 ES 15772173 T ES15772173 T ES 15772173T ES 15772173 T ES15772173 T ES 15772173T ES 2746150 T3 ES2746150 T3 ES 2746150T3
Authority
ES
Spain
Prior art keywords
virus
spp
protein
members
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15772173T
Other languages
English (en)
Spanish (es)
Inventor
Hinh Ly
Yuying Liang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota
Original Assignee
University of Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota filed Critical University of Minnesota
Application granted granted Critical
Publication of ES2746150T3 publication Critical patent/ES2746150T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES15772173T 2014-09-22 2015-09-22 Sistema de genética inversa para el virus Pichindé y métodos de uso Active ES2746150T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462053443P 2014-09-22 2014-09-22
PCT/US2015/051337 WO2016048949A1 (en) 2014-09-22 2015-09-22 Pichinde virus reverse genetics system and methods of use

Publications (1)

Publication Number Publication Date
ES2746150T3 true ES2746150T3 (es) 2020-03-04

Family

ID=54238628

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15772173T Active ES2746150T3 (es) 2014-09-22 2015-09-22 Sistema de genética inversa para el virus Pichindé y métodos de uso

Country Status (12)

Country Link
US (2) US10533159B2 (ja)
EP (1) EP3198008B1 (ja)
JP (1) JP6875274B6 (ja)
KR (1) KR20170057384A (ja)
CN (1) CN107109371A (ja)
AU (1) AU2015321557B2 (ja)
BR (1) BR112017005744B1 (ja)
CA (1) CA2961913A1 (ja)
ES (1) ES2746150T3 (ja)
MX (1) MX2017003694A (ja)
PL (1) PL3198008T3 (ja)
WO (1) WO2016048949A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016048949A1 (en) 2014-09-22 2016-03-31 Regents Of The University Of Minnesota Pichinde virus reverse genetics system and methods of use
EP3778903A1 (en) * 2014-11-13 2021-02-17 Université de Genève Tri-segmented arenaviruses as vaccine vectors
WO2016198531A2 (en) 2015-06-10 2016-12-15 Hookipa Biotech Ag Hpv vaccines
FI3371316T3 (fi) 2015-11-04 2023-01-13 Rokotteita hepatiitti b -virusta vastaan
CN108697775B (zh) 2015-11-12 2023-05-09 霍欧奇帕生物科技有限公司 作为癌症疫苗的沙粒病毒颗粒
EP3458593A1 (en) * 2016-05-18 2019-03-27 Hookipa Biotech GmbH Tri-segmented pichinde viruses as vaccine vectors
EP4192519A2 (en) * 2020-08-06 2023-06-14 Regents of the University of Minnesota Multivalent vaccines against turkey arthritis reovirus
WO2022269362A2 (en) 2021-06-21 2022-12-29 Vaxxinova International B.V. Veterinary viral vector

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2170622B1 (es) 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
CN101801189B (zh) 2007-08-27 2015-08-26 基内塔第四有限责任公司 用于治疗沙粒病毒感染的抗病毒药
EP2240201B1 (en) 2007-12-21 2015-04-22 The Government of The United States of America as represented by the Secretary of The Department of Health and Human Services, Centers for Disease Recombinant rift valley fever (rvf) viruses and methods of use
US8592205B2 (en) * 2007-12-27 2013-11-26 Universitat Zurich Replication-defective arenavirus vectors
WO2011034953A2 (en) 2009-09-16 2011-03-24 The Administrators Of The Tulane Educational Fund Lassa virus-like particles and methods of production thereof
GB201007790D0 (en) 2010-05-10 2010-06-23 Isis Innovation Compositions
WO2011156273A1 (en) 2010-06-06 2011-12-15 Mount Sinai School Of Medicine Recombinant rna viruses and uses thereof
WO2016048949A1 (en) 2014-09-22 2016-03-31 Regents Of The University Of Minnesota Pichinde virus reverse genetics system and methods of use

Also Published As

Publication number Publication date
BR112017005744B1 (pt) 2023-11-28
PL3198008T3 (pl) 2020-03-31
JP6875274B6 (ja) 2021-06-30
EP3198008A1 (en) 2017-08-02
AU2015321557A1 (en) 2017-04-06
US11993789B2 (en) 2024-05-28
EP3198008B1 (en) 2019-05-29
JP6875274B2 (ja) 2021-05-19
US20200165578A1 (en) 2020-05-28
WO2016048949A1 (en) 2016-03-31
AU2015321557B2 (en) 2020-05-14
US10533159B2 (en) 2020-01-14
MX2017003694A (es) 2017-10-12
CN107109371A (zh) 2017-08-29
KR20170057384A (ko) 2017-05-24
JP2017529084A (ja) 2017-10-05
US20170292119A1 (en) 2017-10-12
CA2961913A1 (en) 2016-03-31
BR112017005744A2 (pt) 2017-12-12

Similar Documents

Publication Publication Date Title
ES2746150T3 (es) Sistema de genética inversa para el virus Pichindé y métodos de uso
Powell et al. Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity
US11384339B2 (en) Influenza viruses with mutant PB2 gene segment as live attenuated vaccines
Sheahan et al. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus
Kamlangdee et al. Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene
JP2017529084A5 (ja)
CN104093422A (zh) 基于副流感病毒5的疫苗
EP3382010A2 (en) Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases
Qin et al. Identification of novel T-cell epitopes on infectious bronchitis virus N protein and development of a multi-epitope vaccine
Thakkar et al. The unstructured paramyxovirus nucleocapsid protein tail domain modulates viral pathogenesis through regulation of transcriptase activity
Halbherr et al. Vaccination with recombinant RNA replicon particles protects chickens from H5N1 highly pathogenic avian influenza virus
US20100209451A1 (en) Compositions and Methods Related to Adenovirus Based Delivery of Antigens
WO2021211704A1 (en) Sars cov-2 vaccines and high throughput screening assays based on vesicular stomatitis virus vectors
US20220047697A1 (en) Salmonella vaccine for the treatment of coronavirus
Bergthaler et al. Envelope exchange for the generation of live-attenuated arenavirus vaccines
ES2669018T3 (es) Procedimiento para la vacunación por vía oral/mucosa por medio de levaduras recombinantes
US20230310574A1 (en) Multivalent vaccines against turkey arthritis reovirus
Fernandez Díaz et al. Development and pre-clinical evaluation of Newcastle disease virus-vectored SARS-CoV-2 intranasal vaccine candidate
ES2913063T3 (es) Ensayo y medicamento
Reza et al. WAYS OF MAKING EFFECTIVE AND SAFE VACCINES AGAINST SARS-CoV-2
McCormick Swine influenza: Pathogenesis and prevention